Payment overview · 2025
General Payments
$1,853.74
98 reported records · 25 companies
Healthcare provider profile · identity verified
William Bedingfield, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEMSON, SC · NPI 1598764524
Verified facts
What the public records show
CMS Open Payments records show William Bedingfield, MD received $1,853.74 in general payments during 2025 across 98 reported records.
ABBVIE INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $411.36 | 22.2% | 27 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $183.13 | 9.9% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $153.34 | 8.3% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $136.36 | 7.4% | 7 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $104.48 | 5.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.13 | 5.0% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $82.38 | 4.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76.97 | 4.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.80 | 3.3% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $60.53 | 3.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.43 | 3.3% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $51.50 | 2.8% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $49.44 | 2.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.78 | 2.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.32 | 2.3% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$41.65 | 2.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.61 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.11 | 1.6% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.67 | 1.2% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $20.95 | 1.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.67 | 1.1% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.19 | 1.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.75 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.28 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.91 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,853.74 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $194.45 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $183.13 | 11 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $153.34 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $131.06 | 12 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $122.67 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $104.48 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.43 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $82.38 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76.97 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $74.49 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.19 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.19 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $60.53 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $60.43 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $51.50 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $49.44 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $48.78 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $45.03 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.32 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.32 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $16.36 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 116 |
| Lisinopril | Lisinopril | 302 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 57 |
| Omeprazole | Omeprazole | 271 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 266 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 245 | 59 |
| Losartan Potassium | Losartan Potassium | 209 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 45 |
| Trazodone Hcl | Trazodone Hcl | 187 | 45 |
| Eliquis | Apixaban | 177 | 28 |
| Gabapentin | Gabapentin | 169 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 36 |
| Furosemide | Furosemide | 147 | 36 |
| Tramadol Hcl | Tramadol Hcl | 146 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 24 |
| Metformin Hcl | Metformin Hcl | 133 | 42 |
| Carvedilol | Carvedilol | 130 | 27 |
| Simvastatin | Simvastatin | 120 | 33 |
| Lorazepam | Lorazepam | 115 | 26 |
| Methylprednisolone | Methylprednisolone | 115 | 91 |
| Memantine Hcl | Memantine Hcl | 114 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 27 |
| Donepezil Hcl | Donepezil Hcl | 99 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 37 |
| Potassium Chloride | Potassium Chloride | 96 | 22 |
| Allopurinol | Allopurinol | 92 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 33 |
| Alprazolam | Alprazolam | 80 | 12 |
| Alendronate Sodium | Alendronate Sodium | 78 | 22 |
| Clonazepam | Clonazepam | 77 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 76 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 17 |
| Ezetimibe | Ezetimibe | 72 | 20 |
| Bupropion Xl | Bupropion Hcl | 68 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 13 |
| Ozempic | Semaglutide | 62 | 11 |
| Glimepiride | Glimepiride | 60 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 12 |
| Celecoxib | Celecoxib | 59 | 11 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 58 | 16 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Meloxicam | Meloxicam | 52 | 18 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Synthroid | Levothyroxine Sodium | 48 | 12 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 11 |
| Azithromycin | Azithromycin | 45 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 12 |
| Finasteride | Finasteride | 40 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | 11 |
| Prednisone | Prednisone | 34 | 26 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Famotidine | Famotidine | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 29 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Nystatin | Nystatin | 29 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Meclizine Hcl | Meclizine Hcl | 25 | 17 |
| Dutasteride | Dutasteride | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 16 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 13 |
| Fluconazole | Fluconazole | 21 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Estradiol | Estradiol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Clonidine | Clonidine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,853.74 · 98 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, AUSTEDO XR, BOTOX, BRIUMVI, CAPLYTA, Cologuard Collection Kit, Doc Band, FANAPT, HETLIOZ, Hizentra, INGREZZA, Leqembi, MOUNJARO, NUPLAZID, Ocrevus, Ozempic, QULIPTA, QUTENZA, REXULTI, Rybelsus, Symbravo, Tascenso ODT, The Cologuard Plus Collection Kit, UBRELVY, ULTOMIRIS, VRAYLAR, VYALEV, VYEPTI, VYVGART HYTRULO, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error